HRTX insider trading
NasdaqCM HealthcareHERON THERAPEUTICS, INC. /DE/: insider trade history from SEC Form 4 filings.
About HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Company website: www.herontx.com
HRTX insider activity at a glance
FilingIQ tracks 388 insider transactions for HRTX in filings since Mar 4, 2015. The most recent transaction is dated Aug 6, 2026.
Across the full history, 19 open-market purchases
and 47 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on HRTX insider trades is 55.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest HRTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Politicians who have traded HRTX
Frequently asked
- How many insider trades does FilingIQ track for HRTX?
- FilingIQ tracks 388 Form 4 insider transactions for HRTX (HERON THERAPEUTICS, INC. /DE/), covering filings from Mar 4, 2015 onwards. 18 of those are dated within the last 90 days.
- Are HRTX insiders net buyers or net sellers?
- Across the full Form 4 history for HRTX, 19 transactions (5%) were open-market purchases and 47 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does HRTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is HRTX in?
- HERON THERAPEUTICS, INC. /DE/ (HRTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $218.20M.
Methodology & sources
Every HRTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.